Sign inJoin waitlistJoin the waitlist

Keith Stockerl-Goldstein

Non-Accredited Program Director-Bone Marrow Transplant · Washington University/B-JH/SLCH Consortium

Credentials: · · ·

History

Non-Accredited -Bone Marrow Transplant · Washington University/B-JH/SLCH Consortium
Present
Hematologic Malignancies & Cellular Therapy · Washington University/B-JH/SLCH Consortium
Present
Washington University/B-JH/SLCH Consortium
Present

Stanford University
1994–1996
Internal Medicine
1991–1994
David Geffen Sch of Med at UCLA
1987–1991

Research

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
The Lancet · 2020 · 1,345 citations
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
New England Journal of Medicine · 2016 · 716 citations
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Blood · 2012 · 360 citations

Ravi Vij
61 papers
John DiPersio
52 papers
Geoffrey Uy
40 papers · 1 as a fellow
PW
Peter Westervelt
40 papers
Mark Schroeder
37 papers
Amanda Cashen
36 papers
Camille Abboud
36 papers
KB
Karl Blume
26 papers
Robert Negrin
22 papers
AG
Armin Ghobadi
21 papers · 9 as a fellow
Laura Johnston
19 papers
IP
Iskra Pusic
17 papers

Clinical trials

Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Principal investigator · Terminated · Phase 1
Washington University School of Medicine
2022–2024
Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
Principal investigator · Completed · Phase 2
Washington University School of Medicine
2021–2022
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Principal investigator · Active not recruiting · Phase 2
Washington University School of Medicine
2009–2028
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2024–2030